Taro Pharma (TARO) Misses Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Taro Provides Results for September 30, 2021
October 28, 2021 5:15 PM EDTHAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and six months ended September 30, 2021.
Quarter ended September 30, 2021 Highlights compared to September 30, 2020
Net sales of $132.0 million decreased $10.9 million. Gross profit of $62.0 million (47.0% of net sales compared to 57.1%) decreased $19.5 million. Research and development (R&D) expenses of $12.5 million decreased $4.1 million. Selling, marketing, general and administrative expenses (SG&A) of $23.7 million were in line with the prior year quarter. Settlements and loss... More